Patent dispute resolution, a booster for Ranbaxy
Ranbaxy Laboratories has firmed up after settling a patent dispute with Takeda Pharmaceutical Company regarding a generic version of the Japanese company’s diabetes drug, Actos, in the United States. India’s leading drug maker by sale is trading at the day’s high of Rs 473, stronger by Rs 7 or 1.7%, on the BSE. The shares had opened at Rs 470 and have touched a low of Rs 467 thus far.
“Under the terms of the agreement, Takeda granted Ranbaxy a non-exclusive royalty-free licence to its US patents covering Actos,” Ranbaxy said in a statement.
The agreement allows Ranbaxy to market a low-cost version of Actos in the US starting from August 17, 2012 – almost 19 months after the basic patent over Actos expires in the US on January 17, 2011.
Ranbaxy has preferred the low risk patent settlement route ever since Daiichi Sankyo, the Japanese drug multinational, picked up a majority stake in the company.
source: Business Standard
Similar Posts:
- Ranbaxy & Daiichi Sankyo confirm deal is binding & final
- Hero Honda to replace Ranbaxy in Sensex
- USFDA raises concerns about Ranbaxy’s Toansa plant – Shares fall as much as 9.1% to Rs 421.10
- Ranbaxy gets authorisation for Amlodipine Tablets in Japan
- Buy Ranbaxy Laboratories, target of Rs 183: KRChoksey
Latest Query
- by Sam
Market Stats
Search Our Archives
Research Desk
- Stocks Trading above their 50 day moving average - DMA In Stock Research
- Download free Ebooks based on Technical Analysis In Personal Training
- TOP 100 Stocks with the Highest P/E as on July 14th, 2013 In Stock Research
- TOP 100 Stocks with the Lowest P/E as on July 14th, 2013 In Stock Research
- Charting Pathsala - Your guide to Techincals In Technical Analysis
